Clinical Investigator Development in Solid Tumor Oncology

描述（由申请人提供）：本提案的主要目的是为Spriggs博士及其在以患者为导向的研究领域的职业发展活动提供薪酬支持。斯普里格斯博士目前领导着实体肿瘤小组，有12名初级教员（任命三年以内）。他还直接负责每年一名妇科研究员。斯普里格斯博士自己的研究项目的实验假设是，耐药性的要素是由基因表达的转录后调控控制的。该实验室计划由两个计划项目资助的领导补充。在卵巢项目中，Spriggs博士领导一个与卵巢癌复发后再诱导相关的临床导向项目，作为他的RO1的延伸，最初包括在卵巢PO1中。在癌症化疗项目中，他指导了4个项目的实施，1)HSP90靶向，2)组蛋白去乙酰化酶靶向，3)p53依赖靶向，4)MAPK激酶途径的抑制。这两个项目与MSKCC u01一起，构成了临床转化研究中研究员和初级教师发展的临床研究基础。这一建议代表了一个独特的机会，培训研究员整合实验室研究转录后耐药性与靶向新药的初步临床研究。作为该项目的一部分，Spriggs博士与Dean Bajorin博士共同担任K30临床研究项目的首席研究员，并为第一年的研究员和初级教员提供了一个专门的拨款写作培训项目。在一项相关活动中，我们提出了一种评估肿瘤医学教师的新机制，并建议收集一个固定的数据集，为MSKCC的初级教师的发展创造基准。

DESCRIPTION (provided by applicant): The principal purpose of this proposal is to provide salary support for Dr. Spriggs and his career development activities in the area of patient oriented research. Dr Spriggs currently leads the solid tumor group with 12 junior faculty members (within three years of appointment). He also has direct responsibility for one Gyn Fellow annually. The experimental hypothesis of Dr. Spriggs' own research program is that elements of drug resistance are controlled by post transcriptional regulation of gene expression. This laboratory program is complemented by leadership of two program project grants. In the Ovarian Program, Dr. Spriggs leads a clinically oriented project related to re-induction following relapse in Ovarian cancer as an extension for his RO1 which was initially included in the Ovarian PO1. In the Cancer Chemotherapy Program, he supervises the conduct of 4 projects directed at 1) HSP90 targeting, 2) Histone deacetylase targeting, 3) p53 dependent targeting, and 4) Inhibition of the MAPK kinase pathways. These two programs, along with the MSKCC UO1, form the basis of clinical research for both fellows and junior faculty development in clinical translational research. This proposal represents a unique opportunity to train fellows in the integration of laboratory studies of post transcriptional drug resistance with the initial clinical studies of targeted new agents. As part of this program, Dr Spriggs is the co-principal investigator with Dr. Dean Bajorin of the institutional K30 program for clinical investigation and a specific training program in grant writing is provided for 1st year fellows and for junior faculty members. In a related activity, we propose a novel mechanism for the evaluation of medical oncology faculty and propose to collect a fixed data set to create benchmarks for advancement of junior faculty members at MSKCC.